EUVIMEDEUVIMED entdecken
Open Access

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity

Carlos Torrado iD, Clark R Andersen, Lei Kang, Amanda L Brink, Taiwo Adesoye, Hung Le, Clover J Patterson, Anna Poullard, Jessica A Osburn, Harold N Tan, Mohamed A Gouda, Sheena Charles und 13 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Carlos Torrado und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United Sta…. Hauptthemen laut MEDLINE: Telemedicine, Neoplasms, Health Services Accessibility, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health through MD Anderson's Cancer Center, Clinical and Translational Science Award (CTSA), National Institutes of Health through MD Anderson’s Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Telemedicine expanded rapidly during the COVID-19 pandemic, but its role in early-phase oncology trials remains uncertain. We evaluated its impact on recruitment, enrollment, equity, and access in a large phase I program. Patients and methods We retrospectively analyzed patients seen for first consultation in the MD Anderson Phase I Program (2016-2023). Recruitment (consent) and enrollment (treatment initiation) were compared by visit type, race/ethnicity, and geography across pre-pandemic (2016-2019), pandemic (2020-March 11, 2023), and post–public health emergency (PHE; March-December 2023) periods. A chart review of 400 patients validated findings.

Results

Of 14 085 patients, 7247 were evaluated post-pandemic, with 36% (n = 2616) of first visits by telemedicine. Recruitment and enrollment rates were comparable between telemedicine and in-person visits (61.5% vs 62.6% and 37.5% vs 39.6%, respectively) in the post-2020 period. Hispanic patients used telemedicine more often than non-Hispanic (NH) white patients (43.8% vs 35.9%; P = .0002) and had higher enrollment (54.2% vs 39.4%; P < .0001) during this period. Rates were similar for NH Black vs NH White patients. Texas residents were more likely to use telemedicine than out-of-state patients (48.5% vs 22.8%; P = .0001). After the PHE ended, telemedicine increased among Texas patients (48%→56%) but declined among out-of-state patients (26%→12%).

Conclusions

Telemedicine is a feasible and equitable strategy for early-phase oncology trial enrollment, with strong uptake among Hispanic patients. However, use declined among out-of-state patients after the PHE, underscoring cross-state licensure and reimbursement barriers to equitable access. Policy reforms are essential to preserve telemedicine as a permanent gateway to clinical trials and to broaden diversity in cancer research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelemedicineNeoplasmsHealth Services AccessibilityCOVID-19Clinical Trials, Phase I as TopicMedical OncologyHumansFemaleMaleRetrospective StudiesMiddle AgedSARS-CoV-2Patient SelectionAdultAgedDiversity, Equity, Inclusion

Stichwörter der Autor:innen

access to oncology careearly-phase clinical trialsenrollment barrierspatient recruitmenttelemedicine

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Experimental Therapeutics, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Carlos Torrado, Tin-Yun Tang, Aung Naing, Jordi Rodon, Funda Meric-Bernstam, Siqing Fu

Förderung

  • National Institutes of Health through MD Anderson's Cancer Center
  • Clinical and Translational Science Award (CTSA)
  • National Institutes of Health through MD Anderson’s Cancer Center

Zitieren

APA

Torrado, C., Andersen, C. R., Kang, L., Brink, A. L., Adesoye, T., Le, H., Patterson, C. J., Poullard, A., Osburn, J. A., Tan, H. N., Gouda, M. A., Charles, S., Urschel, G. E., Tang, T. Y., Hong, D. S., Champiat, S., Naing, A., Tsimberidou, A. M., Dumbrava, E. E., …, & Fu, S. (2026). Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity. The Oncologist. https://doi.org/10.1093/oncolo/oyag075

Vancouver

Torrado C, Andersen CR, Kang L, Brink AL, Adesoye T, Le H, et al. Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity. The Oncologist. 2026. doi:10.1093/oncolo/oyag075

BibTeX
@article{Torrado2026,
  author = {Torrado, Carlos and Andersen, Clark R and Kang, Lei and Brink, Amanda L and Adesoye, Taiwo and Le, Hung and Patterson, Clover J and Poullard, Anna and Osburn, Jessica A and Tan, Harold N and Gouda, Mohamed A and Charles, Sheena and Urschel, Gabriele E and Tang, Tin-Yun and Hong, David S and Champiat, Stephane and Naing, Aung and Tsimberidou, Apostolia M and Dumbrava, Ecaterina E and Piha-Paul, Sarina A and Rodon, Jordi and Yap, Timothy A and Pohlmann, Paula R and Meric-Bernstam, Funda and Fu, Siqing},
  title = {Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag075}
}
Kostenlos starten →